Literature DB >> 23815536

Catheterization during adrenal vein sampling for primary aldosteronism: failure to use (1-24) ACTH may increase apparent failure rate.

Gregory A Kline1, Benny So, Valerian C Dias, Adrian Harvey, Janice L Pasieka.   

Abstract

"Successful" adrenal vein catheterization in primary aldosteronism (PA) is often defined by a ratio of >3:1 of cortisol in the adrenal vein vs the inferior vena cava. Non-use of corticotropin (ACTH) during sampling may increase the apparent failure rate of adrenal vein catheterization due to lower cortisol levels. A retrospective study was performed on all patients with confirmed unilateral PA between June 2005 and August 2011. Adrenal vein sampling (AVS) included simultaneous bilateral baseline samples with repeat sampling 15 minutes after intravenous infusion of 250 μg of Cortrosyn (ACTH-S). Successful catheter placement was judged as adrenal cortisol:IVC cortisol of >3:1, applied to both baseline and ACTH-S samples and lateralization of aldosteronism was judged as normalized aldosterone/cortisol (A/C) ratio >3 times the contralateral A/C ratio. In ACTH-S samples, 94% of right-sided catheterizations were biochemically successful with 100% success on the left. Among baseline samples, only 47% of right- and 44% of left-sided samples met the 3:1 cortisol criteria. However, 95% of apparent "failed" baseline cortisol sets still showed lateralization of A/C ratios that matched the ultimate pathology. Non-ACTH-stimulated samples may be incorrectly judged as failed catheter placement when a 3:1 ratio is used. ACTH-stimulated sampling is the preferred means to confirm catheterization during AVS.
© 2013 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23815536      PMCID: PMC8033820          DOI: 10.1111/jch.12096

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  23 in total

1.  Dynamic testing with high-dose adrenocorticotrophic hormone does not improve lateralization of aldosterone oversecretion in primary aldosteronism patients.

Authors:  Gian Paolo Rossi; Chiara Ganzaroli; Diego Miotto; Renzo De Toni; Gaetana Palumbo; Gian Pietro Feltrin; Franco Mantero; Achille C Pessina
Journal:  J Hypertens       Date:  2006-02       Impact factor: 4.844

2.  Primary aldosteronism among newly diagnosed and untreated hypertensive patients in a Swedish primary care area.

Authors:  Christina Westerdahl; Anders Bergenfelz; Anders Isaksson; Christina Nerbrand; Stig Valdemarsson
Journal:  Scand J Prim Health Care       Date:  2011-03       Impact factor: 2.581

3.  High rate of detection of primary aldosteronism, including surgically treatable forms, after 'non-selective' screening of hypertensive patients.

Authors:  Michael Stowasser; Richard D Gordon; Thanuja G Gunasekera; Diane C Cowley; Gregory Ward; Colin Archibald; B Mark Smithers
Journal:  J Hypertens       Date:  2003-11       Impact factor: 4.844

4.  Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents.

Authors:  Paolo Mulatero; Michael Stowasser; Keh-Chuan Loh; Carlos E Fardella; Richard D Gordon; Lorena Mosso; Celso E Gomez-Sanchez; Franco Veglio; William F Young
Journal:  J Clin Endocrinol Metab       Date:  2004-03       Impact factor: 5.958

5.  Prevalence of primary aldosteronism among unselected hypertensive patients: a prospective study based on the use of an aldosterone/renin ratio above 25 as a screening test.

Authors:  Roberto Fogari; Paola Preti; Annalisa Zoppi; Andrea Rinaldi; Elena Fogari; Amedeo Mugellini
Journal:  Hypertens Res       Date:  2007-02       Impact factor: 3.872

6.  Adrenocorticotropic hormone stimulation during adrenal vein sampling for identifying surgically curable subtypes of primary aldosteronism: comparison of 3 different protocols.

Authors:  Teresa M Seccia; Diego Miotto; Renzo De Toni; Gisella Pitter; Franco Mantero; Achille C Pessina; Gian Paolo Rossi
Journal:  Hypertension       Date:  2009-04-06       Impact factor: 10.190

7.  What are the keys to successful adrenal venous sampling (AVS) in patients with primary aldosteronism?

Authors:  William F Young; Anthony W Stanson
Journal:  Clin Endocrinol (Oxf)       Date:  2009-01       Impact factor: 3.478

8.  Cardiovascular outcomes in patients with primary aldosteronism after treatment.

Authors:  Cristiana Catena; GianLuca Colussi; Elisa Nadalini; Alessandra Chiuch; Sara Baroselli; Roberta Lapenna; Leonardo A Sechi
Journal:  Arch Intern Med       Date:  2008-01-14

9.  Adrenal vein sampling for primary aldosteronism: the assessment of selectivity and lateralization of aldosterone excess baseline and after adrenocorticotropic hormone (ACTH) stimulation.

Authors:  Gian Paolo Rossi; Gisella Pitter; Paolo Bernante; Raffaella Motta; Giampietro Feltrin; Diego Miotto
Journal:  J Hypertens       Date:  2008-05       Impact factor: 4.844

10.  Catheterization during adrenal vein sampling for primary aldosteronism: failure to use (1-24) ACTH may increase apparent failure rate.

Authors:  Gregory A Kline; Benny So; Valerian C Dias; Adrian Harvey; Janice L Pasieka
Journal:  J Clin Hypertens (Greenwich)       Date:  2013-04-11       Impact factor: 3.738

View more
  10 in total

1.  11-Deoxycortisol may be superior to cortisol in confirming a successful adrenal vein catheterization without cosyntropin: a pilot study.

Authors:  Naris Nilubol; Steven J Soldin; Dhaval Patel; Muthoni Rwenji; Jianghong Gu; Likhona S Masika; Richard Chang; Constantine A Stratakis; Electron Kebebew
Journal:  Int J Endocr Oncol       Date:  2017-04-27

2.  A Multi-institutional Comparison of Adrenal Venous Sampling in Patients with Primary Aldosteronism: Caution Advised if Successful Bilateral Adrenal Vein Sampling is Not Achieved.

Authors:  Tracy S Wang; Greg Kline; Tina W Yen; Ziyan Yin; Ying Liu; William Rilling; Benny So; James W Findling; Douglas B Evans; Janice L Pasieka
Journal:  World J Surg       Date:  2018-02       Impact factor: 3.352

Review 3.  Surgical treatment of adrenal tumors during pregnancy.

Authors:  Marisa A Bartz-Kurycki; Sophie Dream; Tracy S Wang
Journal:  Rev Endocr Metab Disord       Date:  2022-07-01       Impact factor: 9.306

4.  Screening for Primary Aldosteronism: Whom and How?

Authors:  Michael Doumas; Vasilios Athyros; Vasilios Papademetriou
Journal:  J Clin Hypertens (Greenwich)       Date:  2015-03-10       Impact factor: 3.738

5.  Catheterization during adrenal vein sampling for primary aldosteronism: failure to use (1-24) ACTH may increase apparent failure rate.

Authors:  Gregory A Kline; Benny So; Valerian C Dias; Adrian Harvey; Janice L Pasieka
Journal:  J Clin Hypertens (Greenwich)       Date:  2013-04-11       Impact factor: 3.738

6.  Repeat Adrenal Vein Sampling in Aldosteronism: Reproducibility and Interpretation of Persistently Discordant Results.

Authors:  Gregory A Kline; Alexander Ah-Chi Leung; Davis Sam; Alex Chin; Benny So
Journal:  J Clin Endocrinol Metab       Date:  2021-03-08       Impact factor: 5.958

Review 7.  New Advances in the Diagnostic Workup of Primary Aldosteronism.

Authors:  Martin J Wolley; Michael Stowasser
Journal:  J Endocr Soc       Date:  2017-01-27

8.  Functional Characterization of Adrenocortical Masses in Nononcologic Patients Using 68Ga-Pentixafor.

Authors:  Jie Ding; Anli Tong; Yushi Zhang; Jin Wen; Hui Zhang; Marcus Hacker; Li Huo; Xiang Li
Journal:  J Nucl Med       Date:  2021-07-22       Impact factor: 10.057

9.  A clinical prediction score for diagnosing unilateral primary aldosteronism may not be generalizable.

Authors:  Erik S Venos; Benny So; Valerian C Dias; Adrian Harvey; Janice L Pasieka; Gregory A Kline
Journal:  BMC Endocr Disord       Date:  2014-12-11       Impact factor: 2.763

10.  Prognosis of adrenalectomy guided by computed tomography versus adrenal vein sampling in patients with primary aldosteronism: A systematic review and meta-analysis.

Authors:  Yi Yan; Hui-Wen Sun; Yue Qi
Journal:  J Clin Hypertens (Greenwich)       Date:  2022-01-22       Impact factor: 3.738

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.